The concept of thyroid hormone (TH) analogs that retain the beneficial effects 
of TH excess on lipid lowering and fat metabolism, while avoiding any harmful 
effects on the heart, muscle, bone and other tissues, has interested scientists 
and physicians for several decades. While there have been many attempts to 
develop selective TH receptor (TR) modulators (STRMs) for safe lipid lowering, 
these approaches have failed consistently. This review details recent advances 
in the development of TRβ subtype- and liver-selective STRM analogs, and 
presents the results of preliminary clinical trials with one of these compounds, 
eprotirome (KB-2115; Karo Bio AB).